SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Follow-Up Questions
Scisparc Ltd 'in CEO'su kimdir?
Mr. Amitay Weiss 2020 'den beri şirketle birlikte olan Scisparc Ltd 'in Chief Executive Officer 'ıdır.
SPRC hissesinin fiyat performansı nasıl?
SPRC 'in mevcut fiyatı $4.37 'dir, son işlem günde 14.39% increased etti.
Scisparc Ltd için ana iş temaları veya sektörler nelerdir?
Scisparc Ltd Pharmaceuticals endüstrisine ait ve sektör Health Care 'dir
Scisparc Ltd 'in piyasa değerlemesi nedir?
Scisparc Ltd 'in mevcut piyasa değerlemesi $7.0M 'dir
